Pharming Group N.V. - Product Pipeline Review - 2014

Published: Nov, 2014 | Pages: 38 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Pharming Group N.V. - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Pharming Group N.V. - Product Pipeline Review - 2014', provides an overview of the Pharming Group N.V.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Pharming Group N.V.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Pharming Group N.V. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Pharming Group N.V.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Pharming Group N.V.'s pipeline products

Reasons to buy

- Evaluate Pharming Group N.V.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Pharming Group N.V. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Pharming Group N.V.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Pharming Group N.V. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Pharming Group N.V.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Pharming Group N.V. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Pharming Group N.V. Snapshot 5
Pharming Group N.V. Overview 5
Key Information 5
Key Facts 5
Pharming Group N.V. - Research and Development Overview 6
Key Therapeutic Areas 6
Pharming Group N.V. - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Pharming Group N.V. - Pipeline Products Glance 10
Pharming Group N.V. - Clinical Stage Pipeline Products 10
Phase II Products/Combination Treatment Modalities 10
Phase I Products/Combination Treatment Modalities 11
Pharming Group N.V. - Early Stage Pipeline Products 12
Preclinical Products/Combination Treatment Modalities 12
Discovery Products/Combination Treatment Modalities 13
Pharming Group N.V. - Drug Profiles 14
C1 esterase inhibitor (recombinant) 14
Product Description 14
Mechanism of Action 14
R&D Progress 14
Recombinant Enzyme to Replace Alpha Glucosidase for Pompe Disease 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
Recombinant Enzyme to Replace Alpha-Galactosidase A for Fabry's Disease 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
Recombinant Enzyme to Replace Beta-Cerebrosidase for Gaucher's Disease 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
Recombinant Enzyme to Replace Factor IX for Hemophilia B 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
Recombinant Human Collagen Type 1 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
rhFactor VIII 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Pharming Group N.V. - Pipeline Analysis 25
Pharming Group N.V. - Pipeline Products by Target 25
Pharming Group N.V. - Pipeline Products by Route of Administration 26
Pharming Group N.V. - Pipeline Products by Molecule Type 27
Pharming Group N.V. - Pipeline Products by Mechanism of Action 28
Pharming Group N.V. - Recent Pipeline Updates 29
Pharming Group N.V. - Dormant Projects 32
Pharming Group N.V. - Discontinued Pipeline Products 33
Discontinued Pipeline Product Profiles 33
fibrinogen 33
Pharming Group N.V. - Company Statement 34
Pharming Group N.V. - Locations And Subsidiaries 36
Head Office 36
Other Locations & Subsidiaries 36
Appendix 37
Methodology 37
Coverage 37
Secondary Research 37
Primary Research 37
Expert Panel Validation 37
Contact Us 38
Disclaimer 38

List of Tables
Pharming Group N.V., Key Information 5
Pharming Group N.V., Key Facts 5
Pharming Group N.V. - Pipeline by Indication, 2014 7
Pharming Group N.V. - Pipeline by Stage of Development, 2014 8
Pharming Group N.V. - Monotherapy Products in Pipeline, 2014 9
Pharming Group N.V. - Phase II, 2014 10
Pharming Group N.V. - Phase I, 2014 11
Pharming Group N.V. - Preclinical, 2014 12
Pharming Group N.V. - Discovery, 2014 13
Pharming Group N.V. - Pipeline by Target, 2014 25
Pharming Group N.V. - Pipeline by Route of Administration, 2014 26
Pharming Group N.V. - Pipeline by Molecule Type, 2014 27
Pharming Group N.V. - Pipeline Products by Mechanism of Action, 2014 28
Pharming Group N.V. - Recent Pipeline Updates, 2014 29
Pharming Group N.V. - Dormant Developmental Projects,2014 32
Pharming Group N.V. - Discontinued Pipeline Products, 2014 33
Pharming Group N.V., Subsidiaries 36